Siglec-10 hFc Chimera, Avi, Human
Siglec-10 HFc Chimera, Avi, Human

Immobilized Siglec-10 hFc Chimera, Avi, Human, hFc Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-Siglec-10 Antibody, hFc Tag with the EC50 of 14.6ng/ml determined by ELISA.

Siglec-10 HFc Chimera, Avi, Human

The purity of Siglec-10 hFc Chimera, Avi, Human is greater than 95% as determined by SEC-HPLC.

Siglec-10 HFc Chimera, Avi, Human

Siglec-10 hFc Chimera, Avi, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%

Siglec-10 hFc Chimera, Avi, Human

Siglec-10 is a ligand for CD52, the target of the therapeutic monoclonal antibody Alemtuzumab. It is also reported to bind to Vascular adhesion protein 1 (VAP-1) and to the co-stimulatory molecule CD24 also known as HSA (Heat-stable antigen).Siglecs (sialic acid binding Ig-like lectins) are I-type lectins that belong to the immunoglobulin superfamily. They are characterized by an N-terminal Ig-like V-type domain which mediates sialic acid binding, followed by a varying number of Ig-like C2-type domains. Siglecs 5-11 constitute the CD33/Siglec-3 related group, and are differentially expressed in the hematopoietic system.
Z05818
¥72,752.00

Ask us a question
Product Introduction
Species Human
Protein Construction
Siglec-10 (Met17-Thr546)_x000D_
Accession # Q96LC7-1		 hFc Avi
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 85.8 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 95-110 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • Siglec-10 HFc Chimera, Avi, Human
    • Siglec-10 HFc Chimera, Avi, Human

    Immobilized Siglec-10 hFc Chimera, Avi, Human, hFc Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-Siglec-10 Antibody, hFc Tag with the EC50 of 14.6ng/ml determined by ELISA.

  • Siglec-10 HFc Chimera, Avi, Human
    • Siglec-10 HFc Chimera, Avi, Human

    The purity of Siglec-10 hFc Chimera, Avi, Human is greater than 95% as determined by SEC-HPLC.

  • Siglec-10 HFc Chimera, Avi, Human
    • Siglec-10 HFc Chimera, Avi, Human

    Siglec-10 hFc Chimera, Avi, Human on Bis-Tris PAGE under reduced conditions. The purity is greater than 95%


Background
Target Background Siglec-10 is a ligand for CD52, the target of the therapeutic monoclonal antibody Alemtuzumab. It is also reported to bind to Vascular adhesion protein 1 (VAP-1) and to the co-stimulatory molecule CD24 also known as HSA (Heat-stable antigen).Siglecs (sialic acid binding Ig-like lectins) are I-type lectins that belong to the immunoglobulin superfamily. They are characterized by an N-terminal Ig-like V-type domain which mediates sialic acid binding, followed by a varying number of Ig-like C2-type domains. Siglecs 5-11 constitute the CD33/Siglec-3 related group, and are differentially expressed in the hematopoietic system.
Synonyms SLG2; SIGLEC10; MGC126774; PRO940

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.